Letter to the EditorBenefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia
Section snippets
Acknowledgments
The authors are grateful for the support of the Stanley Medical Research Institute (#01T-400) which provided the funding for the initial trial.
References (3)
- et al.
N-Acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial
Biol. Psychiatry
(2008)
There are more references available in the full text version of this article.
Cited by (10)
Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders
2018, Schizophrenia ResearchCitation Excerpt :In both previous trials and the current study, NAC produced improvement in PANSS total and negative symptoms but failed to improve PANSS positive symptoms. In a subgroup of clozapine treated patients, PANSS total and negative symptoms, but not positive symptoms, were improved by NAC (O. M. Dean et al., 2015). However, a recent NAC trial in early phase schizophrenia failed to demonstrate efficacy for negative symptoms (Conus et al., 2018).
Augmentation strategies for clozapine resistance: A systematic review and meta-analysis
2022, Acta NeuropsychiatricaBiochemical disturbances in schizophrenia — a «window of opportunity»
2022, Obozrenie Psihiatrii i Medicinskoj Psihologii Imeni V.M. BekhterevaEffects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia
2018, Psychopharmacology
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.